<?xml version="1.0" encoding="utf-8"?>
<Journal>
<Journal-Info>
<name>International Journal of Pharma and Bio Sciences</name>
<website>ijpbs.net</website>
<email>editorijpbs@rediffmail.com (or) editorofijpbs@yahoo.com (or) prasmol@rediffmail.com</email>
</Journal-Info>
<article>
<article-id pub-id-type='other'>10.22376/ijpbs.2019.10.1.p1-12</article-id>
<issue_number>Volume 3 Issue 3</issue_number>
<issue_period>2012 (July - September)</issue_period>
<title>Comparative Study Of Effect Of Alpha Glucosidase Inhibitors – Miglitol, Acarbose And Voglibose On Postprandial Hyperglycemia And Glycosylated Hemoglobin In Type-2 Diabetes Mellitus </title>
<abstract>Diabetes mellitus has emerged as a major healthcare problem in India. Management of postprandial plasma glucose (PPG) level is important to prevent the complications associated with type-2 diabetes. Considering paucity of studies motivated us to compare the effect of Acarbose, Miglitol and Voglibose on postprandial hyperglycemia and HbA lessThan sub greaterThan 1C lessThan /sub greaterThan  . It was single blind, randomized, parallel group, comparative, prospective clinical trial on 90 diabetes type 2 patients defined as post prandial plasma glucose (PPG) levels more than 200 mg % and glycosylated haemoglobin more than 7 % at visit 1. Glycosylated hemoglobin (p=0.78) and post prandial blood glucose (p=0.61) was reduced more by Voglibose than Miglitol and Acarbose. Though this finding is not statistically significant, adverse effect profile was better with Voglibose (6.66%) than Miglitol (16.66%) and Acarbose(33.33%). Present study recommends use of Voglibose looking at its efficacy and safety profile as preferential choice in the management of postprandial hyperglycaemia in treatment of type-2 diabetes mellitus.</abstract>
<authors>Dr. Teli Shaikh Emaran Shaikh Ismail,  Dr. Sarang Anantrao Deshmukh</authors>
<keywords>Postprandial hyperglycemia, Miglitol, Acarbose, Voglibose, Glycosylated haemoglobin</keywords>
<pages>337-343</pages>
</article>
</Journal>
